Entospletinib (ENTO) and decitabine (DEC) combination therapy in older newly diagnosed (ND) acute myeloid leukemia (AML) patients with mutant TP53 or complex karyotype is associated with poor response and survival: A phase 2 sub-study of the Beat AML Master Trial Meeting Abstract
| Authors: | Duong, V. H.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Arellano, M. L.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; Litzow, M. R.; Lin, T. L.; Patel, P. A.; Foster, M. C.; Redner, R. L.; Al-Mansour, Z.; Cogle, C. R.; Swords, R. T.; Collins, R. H.; Vergilio, J. A.; Heerema, N. A.; Rosenberg, L.; Yocum, A. O.; Marcus, S.; Chen, T.; Druggan, F.; Stefanos, M.; Gana, T. J.; Shoben, A. B.; Druker, B. J.; Burd, A.; Byrd, J. C.; Levine, R. L.; Boyiadzis, M. M. |
| Abstract Title: | Entospletinib (ENTO) and decitabine (DEC) combination therapy in older newly diagnosed (ND) acute myeloid leukemia (AML) patients with mutant TP53 or complex karyotype is associated with poor response and survival: A phase 2 sub-study of the Beat AML Master Trial |
| Meeting Title: | 63nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398805011 |
| DOI: | 10.1182/blood-2021-151234 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1279 -- Hybrid meeting, also took place online -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work